2 Healthcare Stocks to Buy Now Before They Surge Even Higher

As the healthcare sector continues to grow and evolve, investors are always on the lookout for promising stocks with significant growth potential. Two healthcare stocks that have caught the attention of investors and analysts alike are Amgen (AMGN) and Eli Lilly (LLY). Both companies have strong pipelines, innovative products, and compelling reasons to invest. Let's take a closer look at these two healthcare stocks and explore why they could surge even higher in the near future.



Amgen (AMGN)

Amgen is a biotechnology company that focuses on developing and manufacturing medicines for serious illnesses. The company's stock has been volatile in recent weeks due to the release of data from a phase 2 clinical trial for its weight loss candidate, MariTide. However, David Jagielski, a Motley Fool contributor, believes that the market overreacted to the data, and Amgen's stock is poised for a significant rebound.

Amgen's diverse portfolio of products, attractive valuation, and 3.6% dividend yield make it an appealing investment opportunity. The company's GLP-1/GIPR combination treatment is also expected to offer serious competition to Eli Lilly and Novo Nordisk, further enhancing its growth prospects.



Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company that develops and markets a broad range of branded and generic medicines. The company's shares have been on an upward trajectory, gaining 32% over the past year. Prosper Junior Bakiny, another Motley Fool contributor, highlights several catalysts that could drive Eli Lilly's stock price even higher in 2025.

First, Eli Lilly's tirzepatide (Zepbound and Mounjaro) could receive label expansions, including for reducing the risk of developing type 2 diabetes. Additionally, clinical readouts for tirzepatide in other conditions, such as metabolic dysfunction-associated steatohepatitis, could also boost Eli Lilly's stock price. The company's strong financial results, expanding pipeline, and potential for new products like Kisunla to make an impact further solidify its growth prospects.



In conclusion, Amgen and Eli Lilly are two healthcare stocks that investors should consider buying now before they surge even higher. Both companies have strong pipelines, innovative products, and compelling reasons to invest. As the healthcare sector continues to grow and evolve, these two stocks are well-positioned to capitalize on the industry's trends and opportunities. By investing in Amgen and Eli Lilly, investors can gain exposure to the growing healthcare sector while potentially reaping significant returns.